2015
DOI: 10.1007/7854_2014_365
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological Treatment of Sleep Disorders and Its Relationship with Neuroplasticity

Abstract: Sleep and wakefulness are regulated by complex brain circuits located in the brain stem, thalamus, subthalamus, hypothalamus, basal forebrain, and cerebral cortex. Wakefulness and NREM and REM sleep are modulated by the interactions between neurotransmitters that promote arousal and neurotransmitters that promote sleep. Various lines of evidence suggest that sleep disorders may negatively affect neuronal plasticity and cognitive function. Pharmacological treatments may alleviate these effects but may also have… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 229 publications
0
6
0
Order By: Relevance
“…Obstructive sleep apnea (OSA) is a condition in which the upper airway is obstructed during sleep, producing arousals from sleep and excessive daytime somnolence. OSA is associated with cardiovascular disease and other comorbidities, and may result in cognitive and performance deficits, such as difficulties with cognitive processing, sustaining attention, memory, and executive function [1][2][3][4]. One of the major presenting symptoms of OSA is excessive daytime sleepiness (EDS), which has the potential to significantly impair a patient's healthrelated quality of life (HRQOL), including daily functioning [5][6][7], physical health and functioning [8,9], emotional well-being [6,9], social life [10], and cognition [11].…”
Section: Introductionmentioning
confidence: 99%
“…Obstructive sleep apnea (OSA) is a condition in which the upper airway is obstructed during sleep, producing arousals from sleep and excessive daytime somnolence. OSA is associated with cardiovascular disease and other comorbidities, and may result in cognitive and performance deficits, such as difficulties with cognitive processing, sustaining attention, memory, and executive function [1][2][3][4]. One of the major presenting symptoms of OSA is excessive daytime sleepiness (EDS), which has the potential to significantly impair a patient's healthrelated quality of life (HRQOL), including daily functioning [5][6][7], physical health and functioning [8,9], emotional well-being [6,9], social life [10], and cognition [11].…”
Section: Introductionmentioning
confidence: 99%
“…The used compounds have, independently, potential central nervous system side effects that can limit to varying degrees the functional capacities of the individual. The most common are fatigue, lethargy, somnolence, dizziness, unsteadiness, visual impairment, headache, postural hypotension, weight gain, psychomotor impairment, cognitive impairment, confusion, mood disorders, emotional lability, and even personality changes [ 79 , 80 , 81 , 82 , 83 , 84 , 85 ]. Moreover, combining two or more drugs places the patient in a grey zone where it becomes quite difficult to determine her/his real neurological potential and the actual disease-related symptoms.…”
Section: The Promised Revolution Of New Technologies: a Real Opportun...mentioning
confidence: 99%
“…Sleep promotion interventions include both pharmacological and non-pharmacological treatments. Pharmacological agents that induce sleep provide sedation and analgesia and are commonly used in the ICU setting ( 7 ). However, pharmacological interventions can have negative side effects such as impaired cognitive function, the risk of tolerance or dependency, decreased ventilation, and a disruption in normal sleep physiology ( 8 ).…”
Section: Introductionmentioning
confidence: 99%